Form 8-K - Current report:
SEC Accession No. 0000950170-22-014798
Filing Date
2022-08-04
Accepted
2022-08-04 16:32:40
Documents
14
Period of Report
2022-08-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rlay-20220804.htm   iXBRL 8-K 58637
2 EX-99.1 rlay-ex99_1.htm EX-99.1 241420
3 GRAPHIC img175089203_0.jpg GRAPHIC 7375
  Complete submission text file 0000950170-22-014798.txt   441941

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rlay-20220804.xsd EX-101.SCH 2485
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rlay-20220804_pre.xml EX-101.PRE 11090
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rlay-20220804_lab.xml EX-101.LAB 13562
8 EXTRACTED XBRL INSTANCE DOCUMENT rlay-20220804_htm.xml XML 4766
Mailing Address 399 BINNEY STREET 2ND FLOOR CAMBRIDGE MA 02139
Business Address 399 BINNEY STREET 2ND FLOOR CAMBRIDGE MA 02139 617-370-8837
Relay Therapeutics, Inc. (Filer) CIK: 0001812364 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39385 | Film No.: 221137190
SIC: 2836 Biological Products, (No Diagnostic Substances)